1 – 6 of 6
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia : A review of the literature
(
- Contribution to journal › Scientific review
- 2021
-
Mark
Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A
(
- Contribution to journal › Article
- 2020
-
Mark
Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach
(
- Contribution to journal › Article
-
Mark
Direct comparison of two extended half-life PEGylated recombinant FVIII products : a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
(
- Contribution to journal › Article
- 2019
-
Mark
Direct comparison of two extended-half-life recombinant FVIII products : a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
(
- Contribution to journal › Article
- 2015
-
Mark
Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A.
(
- Contribution to journal › Letter